ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

S A DEAN DROOBY MD

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,461Medicare Part D Prescriptions Filled, Including Refills

Rank: 155 out of 387

$585K Total Retail Price of All Prescriptions

Rank: 107 out of 387

257 Patients Receiving at Least One Drug in Part D
94%Patients 65 Years and Older
0% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oklahoma
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 257 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

13% of this provider’s 257 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

1% of this provider’s 7,105 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$78 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

29 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oklahoma
SIMVASTATIN 454 433 1 5
AMLODIPINE BESYLATE 336 336 2 6
OMEPRAZOLE 265 261 3 4
ZOLPIDEM TARTRATE 232 226 4 16
LEVOTHYROXINE SODIUM 231 202 5 2
ATORVASTATIN CALCIUM 210 207 6 13
ATENOLOL 170 163 7 20
METOPROLOL SUCCINATE 155 155 8 18
LOSARTAN POTASSIUM 151 147 9 24
HYDROCODONE-ACETAMINOPHEN 144 136 S3 10 1
RAMIPRIL 142 138 11 119
CARVEDILOL 142 142 11 21
WARFARIN SODIUM 136 136 13 17
NIASPAN 124 120 14 164
LISINOPRIL 111 111 15 3
NAMENDA 109 109 16 35
BUPROPION XL 103 80 17 219
TRAMADOL HCL 99 94 18 14
DIOVAN 95 89 19 33
EVISTA 90 90 20 111
FUROSEMIDE 87 87 21 7
ALENDRONATE SODIUM 85 85 22 31
ENALAPRIL MALEATE 84 84 23 69
FLUOXETINE HCL 80 76 24 46
TAMSULOSIN HCL 78 75 25 32
CITALOPRAM HBR 78 78 25 19
METFORMIN HCL 75 70 27 8
ALLOPURINOL 72 72 28 28
VERAPAMIL ER 71 70 29 87
CAPTOPRIL 61 61 30 237
GABAPENTIN 61 59 30 10
PAROXETINE HCL 61 56 30 52
SINGULAIR 59 58 33 83
SYNTHROID 56 56 34 68
FLUTICASONE PROPIONATE 55 55 35 29
METOPROLOL TARTRATE 55 55 35 11
BUPROPION HCL SR 54 51 37 158
SERTRALINE HCL 50 28 38 23
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.